J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
|
296.2B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
286.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
239B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
J B Chemicals and Pharmaceuticals Ltd
Glance View
In the bustling marketplace of India's pharmaceutical industry, J B Chemicals and Pharmaceuticals Ltd. has carved its niche, a testament to its strategic vision and operational prowess. Founded in 1976 by Janak Mehta, the company has grown from its humble beginnings into a leading player in both the domestic and international arenas. Originally rooted in the ethos of quality and innovation, it established a firm foothold in the pharmaceutical sector through a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and contract manufacturing. As a vertically integrated company, J B Chemicals leverages its ability to control the manufacturing process from start to finish, ensuring strict quality measures and cost efficiencies, vital in tackling industry competition and regulatory challenges. The heart of J B Chemicals’ revenue model is its well-rounded product line that spans a range of therapeutic categories, including gastrointestinal, cardiovascular, and anticold segments. Blockbuster brands like Cilacar and Metrogyl have propelled the company to the top ranks within India, while its export division flourishes, contributing significantly to total earnings. With footprints in more than 30 countries, particularly in Russia and South Africa, the company taps into the growing demand for generic medicines worldwide. Moreover, by embracing innovation and investing in research and development, J B Chemicals continues to introduce new and improved medical solutions, positioning itself as a dynamic player in meeting global healthcare needs.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for J B Chemicals and Pharmaceuticals Ltd is 18%, which is above its 3-year median of 15.9%.
Over the last 3 years, J B Chemicals and Pharmaceuticals Ltd’s Net Margin has increased from 13.5% to 18%. During this period, it reached a low of 13% on Mar 31, 2023 and a high of 18% on Jan 1, 2026.